- Home
- NX vs GYRE Comparison
NX vs GYRE Comparison
Compare NX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- GYRE
- Stock Information
- Founded
- NX 1927
- GYRE 2002
- Country
- NX United States
- GYRE United States
- Employees
- NX N/A
- GYRE N/A
- Industry
- NX Metal Fabrications
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- GYRE Health Care
- Exchange
- NX Nasdaq
- GYRE Nasdaq
- Market Cap
- NX 1.1B
- GYRE 1.1B
- IPO Year
- NX N/A
- GYRE N/A
- Fundamental
- Price
- NX $22.70
- GYRE $11.19
- Analyst Decision
- NX Strong Buy
- GYRE
- Analyst Count
- NX 1
- GYRE 0
- Target Price
- NX $38.00
- GYRE N/A
- AVG Volume (30 Days)
- NX 328.9K
- GYRE 112.4K
- Earning Date
- NX 03-06-2025
- GYRE 11-13-2024
- Dividend Yield
- NX 1.41%
- GYRE N/A
- EPS Growth
- NX N/A
- GYRE N/A
- EPS
- NX 0.90
- GYRE N/A
- Revenue
- NX $1,277,862,000.00
- GYRE $105,033,000.00
- Revenue This Year
- NX $50.17
- GYRE $25.32
- Revenue Next Year
- NX $2.87
- GYRE $12.95
- P/E Ratio
- NX $25.22
- GYRE N/A
- Revenue Growth
- NX 13.03
- GYRE N/A
- 52 Week Low
- NX $21.48
- GYRE $8.26
- 52 Week High
- NX $39.31
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- NX 35.96
- GYRE 51.52
- Support Level
- NX $21.48
- GYRE $10.41
- Resistance Level
- NX $24.79
- GYRE $11.36
- Average True Range (ATR)
- NX 0.78
- GYRE 0.69
- MACD
- NX 0.20
- GYRE 0.09
- Stochastic Oscillator
- NX 36.86
- GYRE 60.22
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.